MedTrace Logo

Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin

NCT03161132 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-01-27

No results posted yet for this study

Summary

Impact of the combination of Olaparib and Pegylated Liposomal Doxorubicin on improvement of progression-free survival at 6 months in patients with platinum resistant advanced ovarian cancer.

Conditions

  • Advanced Ovarian Cancer

Interventions

DRUG

Olaparib

Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.

DRUG

Pegylated Liposomal Doxorubicin

PLD 40mg/m2 every 28 days intravenous

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Grupo Español de Investigación en Cáncer de Ovario

    lead OTHER

Principal Investigators

  • Alejandro Pérez-Fidalgo, M.D., Ph.D. · University of Valencia, Hospital Clinico Universitario de Valencia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-13
Primary Completion
2020-02-07
Completion
2022-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03161132 on ClinicalTrials.gov